RecruitingNot ApplicableNCT07047807
PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma
Sponsor
Massachusetts General Hospital
Enrollment
50 participants
Start Date
Oct 6, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to refine and pilot test PDAC-PATHWAYS, a digital informational and supportive care app for patients who are initiating neoadjuvant therapy for pancreatic ductal adenocarcinoma (PDAC).
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Age≥18 years
- Within 8 weeks of a documented decision to pursue neoadjuvant therapy for newly diagnosed, non-metastatic PDAC
- Able to comprehend and speak English
Exclusion Criteria1
- Comorbid health condition that would interfere with study participation, as identified by the cancer care team
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BEHAVIORALPDAC-PATHWAYS
A digital app for patients initiating neoadjuvant therapy for PDAC
OTHERUsual Care
Routine treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07047807
Related Trials
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
NCT076217183 locations
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT0756215217 locations
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT0683556912 locations
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT0725223217 locations
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT074914455 locations